Stay updated with breaking news from Code Therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
In less than one year, ReCode Therapeutics has reeled in $200 million in financing. Big pharmaceutical companies are taking notice of the biotech startup’s technology, which enables lipid nanoparticles to go a wide range of organs and tissues, potentially broadening the reach of genetic medicines.
Code Biotherapeutics uses synthetic DNA as the foundation for its genetic medicines, which the startup claims offer several key advantages compared to genetic medicines delivered via engineered viruses. The startup plans to use its new capital to develop lead programs in Duchenne muscular dystrophy and type 1 diabetes.
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) was the recipient of a significant drop in short interest in May. As of May 15th, there was short interest totalling 24,900 shares, a drop of 46.6% from the April 30th total of 46,600 shares. Currently, 0.3% of the shares of the stock are short sold. Based on […]
TransCode Therapeutics, Inc. (NASDAQ:RNAZ – Get Rating) was the recipient of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 24,900 shares, a drop of 46.6% from the April 30th total of 46,600 shares. Currently, 0.3% of the company’s stock are sold short. Based […]
BOSTON, May 20, 2022 -- TransCode Therapeutics, Inc. today announced that it will be presenting at the H.C. Wainwright Global Investment Conference. The in-person venue for the hybrid event is the... | May 20, 2022